Trends in usage and drug costs of immune checkpoint inhibitors in Japan
Drug costs for ICIs are significantly increasing despite the Japanese government's frequent efforts to reduce ICI drug prices. The elderly population made up a particularly high proportion of those burdened with the higher costs. Healthcare economic policies are warranted to ensure efficient distribution of budgetary resources.
Authors
- Ataru Igarashi (ORCID: https://orcid.org/0000-0001-6307-6916)
- Akina Takami (ORCID: https://orcid.org/0009-0004-3289-822X)
- Koki Yamashita (ORCID: https://orcid.org/0009-0005-3187-0900)
Institutions
- Maxwell Technologies (United States) (US)
- Department of Health (IE)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1093/jjco/hyaf178
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05